Percent changes from baseline are reported by treatment group for plasma levels of hsCRP, IL-6, and D-dimer and the inflammation/coagulation rank composite. Comparisons between treatment groups at each follow-up visit after adjustment for baseline level are reported in results
Figure 1: Percent Change in Biomarkers of Inflammation and Coagulation after Continuing Abacavir/Lamivudine (ABC Group) versus switching to Tenofovir DF/ Emtricitabine (TDF Group).